Rare diseases
Investigational molecules
Locations
1 Corporate Drive, 2nd Floor, 94080-7043, United States
The sponsor demonstrates a focused commitment to advancing treatment options for chronic hepatitis B virus infection, addressing both HBeAg-positive and HBeAg-negative patient populations. Research efforts concentrate on developing novel therapeutic agents designed to reduce plasma HBV DNA levels, a critical marker of viral replication and disease activity.
The investigational approach includes comparative evaluation against established nucleotide analogue therapies, specifically examining efficacy outcomes in treatment-naive adult populations across diverse geographical regions.
Aligos Therapeutics Inc. runs clinical trials in conditions such as Chronic hepatitis B, among others.
Clinical trials run by this sponsor – those enrolling participants first.
BulgariaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
